Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZG-801 Phase III Trial - Randomized, Double-blind, Placebo-controlled Trial of ZG-801 in Patients With Hyperkalemia -

Next Previous
X
Search
Trial Profile

ZG-801 Phase III Trial - Randomized, Double-blind, Placebo-controlled Trial of ZG-801 in Patients With Hyperkalemia -

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Sponsors Zeria

    • Most Recent Events

    • 24 Sep 2024 According to a CSL media release, CSL Vifor granted Zeria the exclusive right to develop and market Veltassa in Japan, in 2018. Zeria expects to begin the marketing following National Health Insurance price listing. Veltassa has now received marketing authorizations in 41 countries worldwide, including US and EU.
    • 24 Sep 2024 According to a CSL media release, CLS's partner Zeria Pharmaceutical Co., Ltd. (Zeria) has received marketing authorization approval for Veltassa from the Japan's Ministry of Health and Labor Welfare (MHLW) for the treatment of adult patients with hyperkalemia. The approval is based on Zeria's MA application supported by positive clinical data from the Japanese clinical development program of ZG-801conducted in patients with hyperkalemia in Japan.
    • 18 Apr 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top